Coexistence
Recently, an evaluation report of the PCMA pointed out that patent drug manufacturers have introduced a series of measures on patent drugs that are often used by the elderly in an attempt to restrict the production and sale of such products by generic drug manufacturers. Patent component traps and other measures seek to delay the launch of generic drugs or enter the federal medical insurance system to the greatest extent possible.

